MRI can be a distressing and traumatic experience in many patients, especially in those with underlying anxiety and/or claustrophobia. We conducted a study to determine if dexmedetomidine as a sedative agent can alleviate these symptoms. Dexmedetomidine is a potent and highly selective α-2 adrenergic receptor agonist which has sedative and analgesic properties. Eleven adult patients (n=11) with a histroy of anxiety and/or claustrophobia undergoing MRI who expressed their desire for sedation were recruited. Dexmedetomidine was infused at 0.5 to 1.0 µg/kg over 10 minutes prior to scanning. Eight patients (n=8) were able to complete the MRI scan comfortably. The findings suggest that dexmedetomidine provides adequate sedation that can allow patients with anxiety and/or claustrophobia to undergo MRI scanning succesfully in a large poproption of the population with anxiety. This result however is still preliminary and will need to be validated in a more robust clinical study.
Introduction
MRI is a special technique that produces detailed images of the body's internal environment in order to assist in the diagnosis and monitoring of many medical conditions. Patients encounter a noisy, enclosed and isolated environment because of the design and specific nature of MRI machine, even with the advances made in modern machines technologies.
Under such circumstances, a certain subset of patients would experience tremendous amount of distress, anxiety, agitation and claustrophobia. In extreme cases, these patients would not be able to complete the MRI examination despite the administration of sedatives such as benzodiazepines, opioids and hypnotics. These traditional pharmacological agents may not be very effective in producing adequate sedation that will ensure a motionless patient. It needs to be noted that at high doses these drugs possess possible undesirable adverse effects which may result in apnoea, airway obstruction and hypotension.
The ideal sedative drug that alleviate severe anxiety and/or claustrophobia in MRI has yet to be identified. Dexmedetomidine (Precedex® Hospira,Illinois,USA), a potent and highly selective α-2 adrenergic receptor agonist, has sedative and analgesic properties with a distribution half-life of about 6 minutes and a terminal half-life of about 2 hours. However, there appears to be limited information being mentioned in literatures with regards of using this drug to manage patients with anxiety disorders who are undergoing MRI scanning. The purpose of this study was therefore to explore the potential value of dexmedetomidine, as an optional pharmocological agent, to enable anxious and/or claustrophobic patients to undergo MRI safetly and comfortably, whom would otherwise would not have been able to complete the scan.
Case series
The MRI scanner in our institution, University Malaya Medical Centre (UMMC), is a GE Signa® HDx (Wisconsin, USA) which has a high-field super-conducting magnet of 1.5 T and a tunnel length of 125cm with inner diameter of 70cm.
After obtaining ethics clearance, 11 adult patients (6 females and 5 males) who expressed their desire for sedation and consented to the use of dexmedetomidine for MRI examination, were recruited. They were briefly counselled by one of the 3 authors on what to expect inside the scan tunnel and verbally supported positively to address their fears and anxieties. Over a period of 10 minutes, a dose of dexmedetomidine 0.5 mcg/kg to a maximum of 1.0 mcg/kg was infused when the patient was in the holding area of the MRI suite. This dose range was chosen based on manufacturer's recommendation (1) . The Riker Sedation-Agitation Scale (2) was used to evaluate the patient's sedation/agitation after dexmedetomidine infusion and after MRI completion. Table 2 shows the ranking of sedation using Riker SedationAgitation Scale (SAS). A SAS 7 (dangerous agiation) was not included in the Table 2 because it would be extremely unlikely to achieve this score for this subset of patients.
Once a targeted SAS 3 to 4 was achieved with dexmedetomidine infusion, the patient was wheeled into the scan room. Patients had ear-muffs applied and were provided with a panic button. Standard monitoring consisted of non-invasive blood pressure, pulse oximetry (Sp02) and electrocardiogram. The monitoring of vital signs were continued during the imaging and recorded every 5 minutes. Oxygen supplementation with 3L /minute was given via nasal prongs. Side effects or complications including hypotension, bradycardia, restlessness, allergic reactions and desaturation were documented if were present during the procedure. After the procedure , the patient was monitored in the recovery bay and discharged home when fully conscious and hemodynamically stable. If the patient developed any serious side effect, the patient would be admitted for close observation and further management. In this case series,the duration of MRI examination ranged from 20 minutes to 50 minutes. Table 1 summarises the SAS and outcome of MRI examinations. Eight patients completed the MRI and had stable respiratory and hemodynamic observations. They were satisfied with the sedative drug but patient No. 1 was noted to complaint of dry mouth. Pateint No. 5 had a SAS score of 2 after dexmedetomidine infusion but underwent MRI examination without any respiratory or hemodynamic issues. 11 had a history of cerebrovascular accident in the past. He was on 3 types of antihypertensive medications to manage his hypertension. The blood pressure at baseline was 130/80 mmHg and heart rate 60 beats/minute. He received dexmedetomidine at 0.7 mcg/kg to achieve a targeted SAS 3 before entering the scan room but 15 minutes later while the MRI was underway, his blood pressure dropped to 65/42 mmHg (2 readings) and heart rate to 50 beats/ minute. He quickly responded to a fluid challenge and a bolus of vasopressor. He remained alert and responsive. However, the procedure was abandoned and later he was warded and observed, without further problems. Patient No. 9 rang the panic button after 30 minutes in the MRI and refused to complete the examination. He claimed he was "not fully asleep" and hence was agitated and anxious.
Discussion
MRI can meet the clinical needs quickly and accurately, producing a definitive diagnosis for patients to be manged appropirately and promptly by treating physicians.
Although it is a non-invasive examination, there are several problems that patients face while MRI is in progress, which includes claustrophobia and noisy environment. Claustrophobia contributes heavily to the anxiety and agitation experienced by patients. Claustrophobia represents a big issue since patient's are unable to undergo MRI examination. This is inspite of the use of various sedative drugs. Claustrophobia may be more severe with the use of older MRI machines. The newer MRI machines are designed to reduce this by incorporating wider space for patients to lie. In fact, newer open scanners or scanners with upright systems have been designed to further help reduce claustrophobia in some patients (3) .
If the patient is nervous and claustrophobic, there are several strategies that can help to reduce the anxiety level associated with MRI scan such as providing the patient with a panic button, setting the patient in a prone position for the scan (4), anxiolytics, airing music during scanning and systemic desensitization (5) . If nothing helps, general anaesthesia may be the final option. Reports relating to the incidences of failed MRI examinations due to claustrophobia vary from country to country. Anxiety-related reactions have been reported to occur in approximately 4%-30% of patients undergoing MRI (6) . In 1998, the Department of Biomedical Imaging, UMMC reported that the incidence of failed MRI examinations due to claustrophobia was 0.54% in 3324 patients (7). More recently, Enders et al quoted that 2.3% of all patients scheduled for MRI suffer from claustrophobia (3).
Dexmedetomidine is a centrally-acting dextro-enantiomer of medetomidine and binds to the α 2-adrenergic receptor and produces dose-dependent sedation. Dexmedetomidine is emerging as an effective therapeutic agent in the management of a wide range of clinical conditions with an efficacious and safe profile (8) . In the United States, it is the only drug in its class (α-2 agonist) approved for continuous intravenous sedation of intubated and mechanically ventilated patients in the intensive care setting for not longer than 24 hours. In 2008 the FDA approved new indication for dexmedetomidine, expanding its use for sedation in non-intubated patients in a monitored setting for surgery and other procedures.
Lubish and her co-workers noted that dexmedetomidine offers several advantages over other sedative drugs and the primary benefit of using it is in its minimal respiratory depression as a side effect (9) . Results following the use of dexmedetomidine in children undergoing MRI have been published (10) but there are no reports on dexmedetomidine as a single bolus infusion in severely anxious adults for MRI examinations. This study revealed that 8 out of 11 patients with anxiety and/or claustrophobia benefited from the administration of dexmedetomidine and completed their MRI examination without any significant problems. In these 8 patients vital signs were stable throughout the procedure. The Riker SedationAgitation Scale (Table 2) , a validated and reliable tool for sedation assessment, has established its value in intensive care setting. This was employed in the study because it is descriptive, flexible and most importantly easy to use. . He might have a poor left ventricular ejection fraction of the heart that was unknown to the authors. Co-morbidities of patients receiving this drug have to be carefully screened, particularly cardiac disease because dexmedetomidine causes a dose-dependent decrease in arterial blood pressure and a concomitant decrease in heart rate and cardiac output.
In conclusion, the present study demonstrates that a single bolus dose of dexmedetomidine at 0.5 -1.0 mcg/kg without maintenance may have the potential as a sedative and anxiolytic for anxious and/or claustrophobic patients undergoing MRI. However, further studies are warranted before this drug can be recommended for routine use in clinical practise in view of the limitations of this study.
